Sequenom's Q3 Revenues Nearly Double | GenomeWeb

NEW YORK (GenomeWeb News) – Sequenom reported after the close of the market Thursday that its third-quarter revenues jumped 92 percent from the third quarter of 2012, driven by sales of its MaterniT21 Plus test.

The San Diego-based firm brought in total revenues of $44 million for the three months ended Sept. 30, up from $22.9 million for the third quarter of 2012 and up from $34.9 million in the second quarter of 2013. It beat the consensus Wall Street estimate of $40.6 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."